Home › Myelofibrosis › Texas › Houston
Pag-aaral pangklinika para sa Myelofibrosis sa Houston, TX
19 pag-aaral para sa Myelofibrosis ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Houston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Nagre-recruitPhase 3
- MD Anderson Cancer Center, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Nagre-recruitPhase 1/2
- MD Anderson, Houston
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Nagre-recruitPhase 1/2
- MD Anderson Cancer Center, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Nagre-recruitPhase 1
- The University of Texas, MD Anderson Cancer Center, Houston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Nagre-recruitPhase 3
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- LUMI Research, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Nagre-recruitPhase 1
- University of Texas M. D. Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Nagre-recruitPhase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Nagre-recruitPhase 1/2
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Nagre-recruitPhase 2
- GSK Investigational Site, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Nagre-recruitPhase 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Nagre-recruitPhase 2
- MD Anderson, Houston
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Nagre-recruitPhase 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Houston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Nagre-recruitPhase 3
- U.T. MD Anderson Cancer Center, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Nagre-recruitPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Nagre-recruitPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Pag-aaral para sa Myelofibrosis sa ibang lungsod
- New York City, NY18 pag-aaral
- Boston, MA12 pag-aaral
- Durham, NC12 pag-aaral
- Seattle, WA11 pag-aaral
- Columbus, OH11 pag-aaral
- Miami, FL10 pag-aaral
- Nashville, TN9 pag-aaral
- Cleveland, OH9 pag-aaral
- Baldwin Park, CA9 pag-aaral
- Atlanta, GA9 pag-aaral
- Tampa, FL9 pag-aaral
- Salt Lake City, UT9 pag-aaral
Iba pang pag-aaral sa Houston
- Non-Small Cell Lung Cancer145 pag-aaral
- Kanser sa Suso126 pag-aaral
- Kanser (lahat ng uri)122 pag-aaral
- Metastatic Cancer104 pag-aaral
- Colorectal Cancer103 pag-aaral
- Kanser sa Ovary90 pag-aaral
- Acute Myeloid Leukemia86 pag-aaral
- Kanser sa Baga78 pag-aaral
- Kanser sa Prostate76 pag-aaral
- Kanser ng Endometrium69 pag-aaral
- Kanser sa Pancreas62 pag-aaral
- Melanoma59 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.